Oxford BioMedicaOXBDF 72 EV-to-FCF is -188.24 as of Jul. 02, 2026. GuruFocus rates OXBDF with a GF Score™ of 72/100 and a GF Value™ of $7.14 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 331 Biotechnology companies, Oxford BioMedica ranks worse than 302114.5% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Oxford BioMedica's Enterprise Value is $1,064.7 Mil.
Oxford BioMedica's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-5.7 Mil. Therefore, Oxford BioMedica's EV-to-FCF for today is -188.24.
The historical rank and industry rank for Oxford BioMedica's EV-to-FCF or its related term are showing as below:
OXBDF'
s EV-to-FCF Range Over the Past 10 Years
Min: -248.57 Med: -9.13 Max: 637.64
Current: -192.15
During the past 13 years, the highest EV-to-FCF of Oxford BioMedica was 637.64. The lowest was -248.57. And the median was -9.13.
OXBDF's EV-to-FCF is ranked worse than 100% of 331
companies
in the Biotechnology industry
Industry Median: 15.9
vs OXBDF: -192.15
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Oxford BioMedica's PE Ratio (TTM) for today is calculated as:
Oxford BioMedica's share price for today is $7.925.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Oxford BioMedica's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.365.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Oxford BioMedica EV-to-FCF Related Terms
Oxford BioMedica EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Oxford BioMedica's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Oxford BioMedica's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oxford BioMedica EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oxford BioMedica's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Oxford BioMedica's EV-to-FCF falls into.
Oxford BioMedica's current Enterprise Value is $1,064.7 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Oxford BioMedica's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-5.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oxford BioMedica (OXBDF) has a EV-to-FCF of -188.24 as of Jul. 02, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Oxford BioMedica and its competitors. According to the industry distribution chart, Oxford BioMedica ranks #999999 out of 331 companies in the Biotechnology industry.
Is Oxford BioMedica's EV-to-FCF too high?
Oxford BioMedica's current EV-to-FCF is -188.24. Based on the distribution chart, Oxford BioMedica ranks #999999 out of 331 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Oxford BioMedica has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oxford BioMedica's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oxford BioMedica ranks #999999 out of 331 companies for EV-to-FCF. This places Oxford BioMedica in the lower half of its industry. The industry median EV-to-FCF is 15.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.90, based on 331 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Oxford BioMedica and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oxford BioMedica's current EV-to-FCF is -188.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxford BioMedica stock overvalued right now?
Based on GuruFocus' analysis, Oxford BioMedica (OXBDF) is currently considered Modestly Overvalued. The stock's GF Value™ is $7.14, compared to a current price of $7.93 — trading 11% above its estimated fair value. The current EV-to-FCF is -188.24. Oxford BioMedica's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Oxford BioMedica (OXBDF), the current EV-to-FCF is -188.24 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oxford BioMedica (OXBDF) Overvalued in 2026?
Based on GuruFocus' analysis, Oxford BioMedica stock appears to be overvalued.
The current stock price of $7.93 is trading 11% above its estimated GF Value™ of $7.14.
GuruFocus considers Oxford BioMedica to be Modestly Overvalued.
Key valuation signals for OXBDF:
EV-to-FCF: -188.24
GF Value™: $7.14 vs. price of $7.93 (11% above fair value)
No single metric tells the full story. See the OXBDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oxford BioMedica PLC is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. The company specializes in viral vector development and manufacturing for cell and gene therapy, with expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Geographically, it derives maximum revenue from the United States, and the rest from Europe, the UK, and the Rest of the world.
72GF Score
Get the complete analysis for OXBDF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OXBDF has been successfully added to your 
